Nuclear factor κB as a target for new drug development in myeloid malignancies

Haematologica

Volumn 92, Issue 9, 2007, Pages 1224-1229

  Cilloni, Daniela ^a   Martinelli, Giovanni ^b   Messa, Francesca ^a   Baccarani, Michele ^b   Saglio, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute myeloid leukemia; Chronic myelogenous leukemia; NF B; Proteasome inhibitors

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; BORTEZOMIB; FLAVOPIRIDOL; HISTONE DEACETYLASE INHIBITOR; I KAPPA B KINASE INHIBITOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; FATIGUE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING; DRUG ANTAGONISM; METABOLISM; MYELOID LEUKEMIA; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 36348988506     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11199     Document Type: Review

References (49)

1. Aggarwall BB. Nuclear factor-κB: the enemy within cancer. Cancer Cell 2004;6:203-8.
2. Ghosh S, May MJ, Kopp EB. NF-κB ad Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
3. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004;18: 2195-24.
4. Malek S, Chen Y, Huxford T, Ghosh G. IκBα, but not IκBα functions as a classical cytoplasmatic inhibitor of NF-κB dimmers by masking both NF-κB nuclear localization sequences in resting cells. J Biol Chem 2001; 276:45225-35.
5. Huang TT, Kudo N, Yoshida M, Miyamoto S. A nuclear export signal in the N terminal regulatory domain of IκBα controls cytoplasmatic localization of inactive NF-κB/Iκbα complexes. Proc Natl Acad Sci 2000; 97:1014-9.
6. Senftleben U Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation of IKKα of a second, evolutionary conserved β NF-κB signalling pathway. Science 2001;293: 1495-9.
7. Takebayashi T, Higashi H, Sudo H, Ozawa H, Suzuki E, Shirado O, et al. NF-κB-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor derived pRB mutants. J Biol Chem 2003;278: 14897-905.
8. Karin M, Yamamoto Y, Wang QM. The IKK NF-λB system: a treasure trove for drug development. Nat Rev 2004;3:17-26:
9. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
10. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res 1999; 59: 2615-2622.
11. Perkins ND. NF-κB: tumor promoter or suppressor? Trends Cell Biol 2004; 14:64-9.
12. Luo JL, Maeda S, Hsu LC, Yagita H, Karin N. Inhibition of NF-κ in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004;6:297-305.
13. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-κB functions as a tumor promoter in inflammation-associated cancer. Nature 2004;431:461-6.
14. Greten FR Eckmann L, Greten TF, Park JM, Li ZW, Egan Lj, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
15. Rayet B, Gelinas C. Aberrant rel/NF-κB genes and activity in human cancer. Oncogene 1999;18:6938-47.
16. Kumatori A, Tanaka K, Inamura N, Stone S, Ogura T, Matsumato T, et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990; 87:7071-5.
17. Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G. Mechanisms of Bcr-Abl mediated NF-κB/Rel activation. Exp Hematol 2003;31:504-11.
18. Deveraux Q, Reed J. IAP family proteins-suppressor of apoptosis. Genes dev 1999;13:239-52.
19. + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004;103:3175-84.
20. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNFa induced apoptosis by NF-κB. Science 1996;274:787-9.
21. Wang CY, Mayo MW, Baldwin AS jr. TNFα and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
22. Bonnet D, Dick J. Human acute myeloid leukaemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
23. Lowenberg B, Downing J, Burnett A. Acute myeloid leukaemia. N Engl J Med 1999;341:1051-62
24. Jordan C. Unique molecular and cellular features of acute myelogenous leukaemia stem cells. Leukemia 2002;16:559-62.
25. Guzman M, Neering S, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor κB is constitutively activated in primitive human acute myelogenous leukaemia cells. Blood 2001;98:2301-7.
26. Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M, et al. Increased IκB kinase activity is associated with activated NF-κB in acute myeloid blasts. Leukemia 2002;12: 2062-71.
27. Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P, et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2 induceo apoptosis of human acute myeloid leukaemia cells. Blood 2005; 105:804-11.
28. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, vadhan-Raj S, et al. Expression of constitutively active nuclear factor κB RelA transcription factor in blasts of acute myeloid leukaemia. Human Pathol 2004;35:246-53.
29. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-λB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 2005; 106: 3917-25.
30. Grossmann M, Metcalf D, Merryfull J, Beg A, Baltimore D, Gerondakis S. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci USA 1999;96:11848-53.
31. Nakata S, Matsumura I, Tanaka K, Ezoe S, Satoh Y, Ishikawa J, et al. NF-κB family proteins participate in multiple steps of hematopoiesis through elimination of reactive oxygen species. J Biol Chem 2004;279:55578-86.
32. Schepers H, Eggen BJ,, Schuringa JJ, Vellenga E. Constitutive activation of NF-κ B is not sufficient to disturb normal steady-state hematopoiesis. Haematologica 2006;91:1710-1.
33. + cells. Leukemia 2003;17:1190-2.
34. Cortes J, Thomas D, Koller C, Giles F, Estey E, Federl S, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004;10:3371-6.
35. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987;84:6558-62.
36. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994;83:1179-87.
37. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995;86:1148-58.
38. Danial NN, Rothman P. JAK-STAT signalling activated by Abl oncogenes. Oncogene 2000;19:2523-31.
39. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS A requirement for NF-κB activation in BCR-ABL mediated transformation. Genes Dev 1998;12:968-81.
40. Finco TS, Westwick JK, Norrin JL, Beg AA, Der CL, Baldwin AS. Oncogenic Ha-Ras-induced signalling activates NF-κB transcriptional activity, which is required for cellular transformation. J Biol Chem 1997;272:24113-6.
41. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr-Abl positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003;88:853-63.
42. Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E, et al. The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 2006;20:61-7.
43. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 2004;104:509-18.
44. Jagannath S, Richardson PG, Barlogie B, Berenson J, Singhal S, Irwin D, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-34.
45. Richardson PG, Barlogie B, Berenson J, Singhal S ,Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
46. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
47. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
48. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-κ B activation and cellular proteasome activity. J Biol Chem 2001; 276:44641-6.
49. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003;102: 3765-74.